RDN2150 (TFA)

• Description:

  RDN2150 (Compound 25) TFA is a ZAP-70 inhibitor (IC50: 14.6 nM) . RDN2150 TFA covalently binds to the C346 residue of ZAP-70. RDN2150 TFA inhibits the expression of CD25 and CD69, and inhibits CD4+ T cell activation. RDN2150 TFA can be used for research of psoriasis[1].

• UNSPSC:

  12352005

• Target:

  Tyrosinase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/rdn2150-tfa.html

• Concentration:

  10mM

• Purity:

  99.80

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(N=C(N2C1=NC=C2)NCC3=CC(NC(C=C)=O)=C(C=C3)Cl)NC4=CC(OC)=C(C=C4)N5CCOCC5)N.OC(C(F)(F)F)=O

• Molecular Formula:

  C30H30ClF3N8O6

• Molecular Weight:

  691.06

• References & Citations:

  [1]Rao D, et al. Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis. J Med Chem. 2023 Aug 18.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported